BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

SVA upcoming catalysts

Sinovac Biotech Co., Ltd: 3 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 8 readout(s) and 0 FDA event(s). Subscribe to SVA (.ics).

Drugs: Verorab®, experimental vaccine, Rabies Vaccine, Freeze-dried, Rabies vaccine

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-30 est.P3Sinovac Biotech Co., Ltd SVANCT07055295 Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis RegimenRabiesnot yet recruiting390
2027-01 est.P3Sinovac Biotech Co., Ltd SVANCT07505836 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 MonthsEpidemic Meningitis; Meningococcal Vaccinesrecruiting1040
2027-01-30 est.P3Sinovac Biotech Co., Ltd SVANCT07055893 Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis RegimenRabies (Healthy Volunteers)not yet recruiting390

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Sinovac Biotech Co., Ltd SVANCT07505888 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 YearsEpidemic Meningitis; Meningococcal Vaccinesactive not recruiting660
2026-07-15P3Sinovac Biotech Co., Ltd SVANCT07416110 Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies VaccineRabies (Healthy Volunteers)active not recruiting912
2026-06-26P3Sinovac Biotech Co., Ltd SVANCT07211152 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant WomenInfluenzacompleted150
2026-05-31 est.P1/P2Sinovac Biotech Co., Ltd SVANCT07400003 Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA VaccineHerpes Zoster; mRNA Vaccinerecruiting519
2026-01-15 est.P2Sinovac Biotech Co., Ltd SVANCT07055880 Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)Rabiesnot yet recruiting120
2025-12-30P1/P2Sinovac Biotech Co., Ltd SVANCT06754384 Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).Hand, Foot, and Mouth Disease (HFMD); Herpanginacompleted552
2025-12-19P1/P2Sinovac Biotech Co., Ltd SVANCT06063057 Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical TrialHand, Foot and Mouth Disease; Herpanginacompleted744
2025-11-30 est.P3Sinovac Biotech Co., Ltd SVANCT06734832 Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)Hand, Foot, and Mouth Disease(HFMD)recruiting8000

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.